PLEGRIDY

Peak

peginterferon beta-1a

BLAINJECTIONINJECTABLE
Approved
Aug 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
13

Mechanism of Action

12.1 Mechanism of Action The mechanism by which PLEGRIDY exerts its effects in patients with multiple sclerosis is unknown. 12.2 Pharmacodynamics There is no biochemical or physiologic effect known to relate directly to the clinical effect of PLEGRIDY. 12.3 Pharmacokinetics After single-dose or…

Pharmacologic Class:

Interferon beta

Clinical Trials (5)

NCT04655222N/ACompleted

Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program

Started Apr 2021
470 enrolled
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
NCT03958877Phase 3Active Not Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Started Oct 2019
152 enrolled
Multiple Sclerosis, Relapsing-Remitting
NCT03870763Phase 3Terminated

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

Started Mar 2019
11 enrolled
Multiple Sclerosis, Relapsing-Remitting
NCT03091569Phase 4Completed

Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy

Started Mar 2017
23 enrolled
Relapsing-Remitting Multiple Sclerosis
NCT02587065Phase 4Completed

Plegridy Satisfaction Study in Participants

Started Feb 2016
193 enrolled
Relapsing-Remitting Multiple Sclerosis (RRMS)